Defunct Company
Total Trials
13
As Lead Sponsor
5
As Collaborator
8
Total Enrollment
1,197
NCT00014664
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase: Phase 2
Role: Lead Sponsor
Start: Oct 31, 2000
Completion: Not specified
NCT00267306
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
Phase: Phase 1/2
Role: Collaborator
Start: Jan 31, 2004
Completion: Dec 31, 2006
NCT00325793
IV Double and Triple Concentrated Nicardipine for Stroke and ICH
Phase: Phase 4
NCT00099970
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
Start: Dec 31, 2004
Completion: Mar 31, 2006
NCT00267709
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
Start: Feb 28, 2005
NCT00267722
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
NCT00109161
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Start: Apr 30, 2005
Completion: Oct 31, 2006
NCT00281294
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
Start: Dec 31, 2005
NCT00279422
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Phase: Phase 2/3
Start: Feb 28, 2006
Completion: Aug 31, 2007
NCT00279435
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
Start: Aug 31, 2006
NCT00355901
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
Phase: N/A
Start: Sep 30, 2006
Completion: Nov 30, 2012
NCT00548717
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
Start: Oct 31, 2007
Completion: Sep 30, 2013